| Item | Cat. No. | Application | Isotype |
| Anti-SARS-CoV-2 Spike RBD mAbs [Enuzovimab Biosimilar] (MABL-4663) | MABL-4663 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-HIV-1 gp120 mAbs [Elipovimab Biosimilar] (MABL-4633) | MABL-4633 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-SLAMF7/CD319 mAbs [Elotuzumab Biosimilar] (MABL-4634) | MABL-4634 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E mAbs [Elranatamab Biosimilar] (MABL-4635) | MABL-4635 | ELISA, FACS, Functional assay, in vivo binding | G2;G2, Kappa;Kappa |
| Anti-ENTPD1/CD39 mAbs [Eltivutabart Biosimilar] (MABL-4636) | MABL-4636 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8 mAbs [Eltrekibart Biosimilar] (MABL-4637) | MABL-4637 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-SIGLEC3/CD33/p67;CD3E mAbs [Eluvixtamab Biosimilar] (MABL-4638) | MABL-4638 | ELISA, FACS, Functional assay, in vivo binding | na;na, Kappa;Lambda |
| Anti-CSF1R/CD115/M-CSFR mAbs [Emactuzumab Biosimilar] (MABL-4639) | MABL-4639 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IFNG mAbs [Emapalumab Biosimilar] (MABL-4640) | MABL-4640 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-SIGLEC3/CD33/p67;CD3E mAbs [Emerfetamab Biosimilar] (MABL-4641) | MABL-4641 | ELISA, FACS, Functional assay, in vivo binding | na;na, Kappa;Lambda |
| Anti-CD3E;CD19 mAbs [Emfizatamab1 Biosimilar] (MABL-4642) | MABL-4642 | ELISA, FACS, Functional assay, in vivo binding | na;G1, Kappa;Kappa |
| Anti-PDL1/CD274;TNFRSF9/CD137/4-1BB mAbs [Emfizatamab2 Biosimilar] (MABL-4643) | MABL-4643 | ELISA, FACS, Functional assay, in vivo binding | na;na, Kappa;Kappa |
| Anti-F9;F10 mAbs [Emicizumab Biosimilar] (MABL-4644) | MABL-4644 | ELISA, FACS, Functional assay, in vivo binding | G4;G4, Kappa;Kappa |
| Anti-MET/HGFR mAbs [Emibetuzumab Biosimilar] (MABL-4645) | MABL-4645 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-VTCN1/B7H4 mAbs [Emiltatug Biosimilar] (MABL-4646) | MABL-4646 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-FLT3/CD135/FLK2;CD3E mAbs [Emirodatamab Biosimilar] (MABL-4647) | MABL-4647 | ELISA, FACS, Functional assay, in vivo binding | na;na, Kappa;Lambda |
| Anti-C2 mAbs [Empasiprubart Biosimilar] (MABL-4648) | MABL-4648 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-TMEM219/IGFBP-3R mAbs [Ebrasodebart Biosimilar] (MABL-4617) | MABL-4617 | ELISA, FACS, Functional assay, in vivo binding | G4, Lambda |
| Anti-C3d mAbs [Ebribafusp Biosimilar] (MABL-4618) | MABL-4618 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-PCSK9 mAbs [Ebronucimab Biosimilar] (MABL-4619) | MABL-4619 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
